BridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company focused on discovering, developing, and delivering medicines for patients with genetic diseases. The company aims to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since its founding 10 years ago, BridgeBio Pharma has advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with its approved medicines, and the company has obtained U.S. Food and Drug Administration (FDA) approval for three products. The company operates with a decentralized hub and spoke model, achieving an average investment per program of less than $40.0 million to proof-of-concept data and less than $10.0 million to reach Investigational New Drug (IND) submission. In addition to its commercial products, led by Attruby, BridgeBio Pharma plans to pursue regulatory submissions for several advanced product candidates, including therapies for achondroplasia, limb-girdle muscular dystrophy type 2I/R9, and autosomal dominant hypocalcemia type 1, all of which have recently released positive Phase 3 data. Since inception, the company has generated 19 investigational new drug applications and contributed to more than 70 peer-reviewed scientific publications. BridgeBio Pharma is a commercial-stage biopharmaceutical company with multiple approved products, a growing global commercial footprint, and a portfolio of late-stage development programs.